Noticias de AKBA_US

Noticias del mercado

Últimas noticias sobre AKBA_US — 158 novedades recientes. Análisis, balances, opiniones y cobertura de prensa.

Ticker: AKBA_US ✕ 158 resultados
18/04/2026 AKBA_US — GuruFocus
Akebia Therapeutics Expects to Resubmit Vadadustat NDA in Third Quarter 2023
18/04/2026 AKBA_US — MSN
H.C. Wainwright Initiates Coverage of Akebia Therapeutics (AKBA) With Buy Rating
17/04/2026 AKBA_US — DirectorsTalk Interviews
Akebia Therapeutics, Inc. (AKBA) Stock Analysis: Potential Upside of 225.93% Draws Investor Attention
16/04/2026 AKBA_US — Intellectia AI ES ← EN
AKBA ¿Debería comprar?
15/04/2026 AKBA_US — MarketBeat
Akebia Therapeutics, Inc. (NASDAQ:AKBA) Given Consensus Rating of "Moderate Buy" by Brokerages
15/04/2026 AKBA_US — Stock Titan
Akebia Therapeutics (NASDAQ: AKBA) asks shareholders to increase authorized stock
13/04/2026 AKBA_US — GuruFocus
Akebia (AKBA) Initiates Phase 1 Trial for AKB-9090 Targeting Kid
13/04/2026 AKBA_US — MarketScreener
Akebia Therapeutics Announces First Participants Dosed in Phase 1 Clinical Trial of AKB-9090
13/04/2026 AKBA_US — GlobeNewswire
Akebia Therapeutics Announces First Participants Dosed in Phase 1 Clinical Trial of AKB-9090
13/04/2026 AKBA_US — Yahoo Finance
Akebia Therapeutics Announces First Participants Dosed in Phase 1 Clinical Trial of AKB-9090
13/04/2026 AKBA_US — simplywall.st
Akebia Therapeutics Leads The Pack Of 3 Promising Penny Stocks
13/04/2026 AKBA_US — GlobeNewswire
Akebia Therapeutics Announces First Participants Dosed in Phase 1 Clinical Trial of AKB-9090
13/04/2026 AKBA_US — GlobeNewswire
Akebia Therapeutics Announces First Participants Dosed in Phase 1 Clinical Trial of AKB-9090
13/04/2026 AKBA_US — Yahoo Finance
Akebia Therapeutics Leads The Pack Of 3 Promising Penny Stocks
13/04/2026 AKBA_US — Stock Titan
Akebia starts human testing of drug for kidney injury after heart surgery
12/04/2026 AKBA_US — ADVFN
Akebia Therapeutics Reports Third Quarter 2025 Financial Results and Recent Business Highlights
09/04/2026 AKBA_US — MarketBeat
Akebia Therapeutics (NASDAQ:AKBA) Rating Increased to Hold at Zacks Research
07/04/2026 AKBA_US — GuruFocus
BTIG Reiterates Buy Rating on AKBA with $4.00 Price Target | AKB
07/04/2026 AKBA_US — Yahoo Finance
Akebia Therapeutics to Conduct Investor Meetings at the Raymond James 2026 Biotech Innovation Symposium
07/04/2026 AKBA_US — Stock Titan
Akebia executives head to New York for Apr. 14 biotech investor meetings

Página 5 de 8

keyboard_arrow_up